Status:
WITHDRAWN
A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants
Lead Sponsor:
AbbVie
Conditions:
Healthy Volunteers
Eligibility:
FEMALE
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the bioavailability of two different doses of venetoclax new high drug load formulation tablets relative to two tablets of the currently marketed venetoclax tabl...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) is \>= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal.
- A condition of general good health based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).
- Participant must be postmenopausal, permanently surgically sterile, or perimenopausal or premenopausal and practicing a method of birth control until at least 1 month after the last dose of study drug.
Exclusion
- \- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Key Trial Info
Start Date :
October 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 28 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06070948
Start Date
October 5 2023
End Date
July 28 2025
Last Update
June 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Acpru /Id# 259897
Grayslake, Illinois, United States, 60030